Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Huaier Granule on Idiopathic Membranous Nephropathy
NCT05839314Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of huaier granule in idiopathic membranous nephropathy (IMN) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Overall clinical remission rate at 96 weeks. Started May 2023; status: recruiting.
02
Drugs
huaier granule
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT05839314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05839314.